By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Supernus Pharmaceuticals 

1550 East Gude Drive

Rockville  Maryland  20850  U.S.A.
Phone: 301-838-2501 Fax: n/a


Key Statistics

Ownership: Public

Web Site: Supernus
Symbol: SUPN


Company News
Supernus (SUPN) Announces First Quarter 2017 Financial Results 5/10/2017 6:25:31 AM
Supernus (SUPN) To Host First Quarter 2017 Earnings Conference Call 4/27/2017 12:22:21 PM
Supernus (SUPN) Receives Final FDA Approval For Trokendi XR For Migraine Prophylaxis In Adults And Adolescents 4/6/2017 11:30:02 AM
Supernus (SUPN) Announces Settlement With Zydus Pharmaceuticals (USA) Inc. On Trokendi XR Patent Litigation 3/7/2017 10:58:32 AM
Supernus (SUPN) Announces Record Fourth Quarter and Full Year 2016 Financial Results 3/1/2017 11:31:23 AM
Supernus (SUPN) To Host Fourth Quarter And Full Year 2016 Earnings Conference Call 2/14/2017 11:37:20 AM
Supernus (SUPN) Announces Issuance Of Eighth U.S. Patent Protecting Trokendi XR 2/8/2017 9:19:14 AM
Supernus (SUPN) Announces Issuance Of Seventh U.S. Patent Protecting Trokendi XR 1/30/2017 7:44:58 AM
Supernus (SUPN) Files Form 10-Q For Third Quarter 2016 And Is Now Current With All Financial Filings 1/24/2017 7:15:11 AM
Supernus (SUPN) Wins Appeal Case On Oxtellar XR 12/13/2016 8:12:46 AM